Baird raised the firm’s price target on Arcellx to $63 from $52 and keeps an Outperform rating on the shares. The firm noted through the expansion of the collaboration with Kite, Arcellx will receive $285M upfront , as Kite opts-in to license the ARC-SparX technology in multiple myeloma and the CART-ddBCMA expands into lymphomas.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACLX: